Brief: MEI Pharma And Kyowa Kirin Announce Discontinuation Of Zandelisib Development Outside Of Japan

Kyowa Kirin

05/12/2022 22:29

Dec 5 (Reuters) - Kyowa Kirin Co Ltd  4151.T :
    * MEI PHARMA AND KYOWA KIRIN ANNOUNCE DISCONTINUATION OF
ZANDELISIB DEVELOPMENT OUTSIDE OF JAPAN FOLLOWING RECENT FDA
MEETING
    * DISCONTINUING GLOBAL DEVELOPMENT OF ZANDELISIB OUTSIDE OF
JAPAN
FOR B-CELL MALIGNANCIES
    * KYOWA KIRIN IS CONTINUING ONGOING CLINICAL TRIALS
INCLUDING
PHASE 2 MIRAGE STUDY
    * KYOWA KIRIN WILL EXPLORE POTENTIAL FOR A SUBMISSION TO
JAPANESE
HEALTH AUTHORITIES BASED ON DATA FROM MIRAGE AND TIDAL TRIALS

Source text for Eikon:  ID:nBw32gQr9a 
Further company coverage:  4151.T 
 ((Reuters.Briefs@thomsonreuters.com))